EPISODE · Aug 12, 2026 · 33 MIN
Should I Invest in SpaceX? (Lessons from SpaceX IPO)
from Money Meets Medicine · host Jimmy Turner, Justin Harvey CFP
SpaceX priced at $135 a share, raised $75 billion, and hit an all-time high of $225 within days — then fell to $107. Dr. Jimmy Turner and Justin Harvey CFP break down how index funds actually decide what gets included in the index, why the S&P 500 said no to SpaceX while CRSP and the Russell 1000 said yes, and what that means for the total stock market index fund in your 401(k). What you'll learn: Why an index fund doesn't pick stocks — it follows 3 rules: seasoning, profitability, and float How Nasdaq, Russell 1000, and CRSP cut IPO seasoning for SpaceX Why your money in an IPO often funds the private investors cashing out on the other side What Dimensional's 12-month IPO exclusion says about buying at the offering How to handle FOMO before Anthropic and OpenAI potentially go public Resources mentioned: Looking to lower your taxes? Check out Gelt, the tax team Jimmy uses: https://moneymeetsmedicine.com/CPA Juno — Looking for a lower interest rate on your student loans? Use group negotiated rates from Juno here: moneymeetsmedicine.com/juno Every physician needs disability insurance. Get quotes from Money Meets Medicine Disability Insurance: https://moneymeetsmedicine.com/disability The Physician Philosopher's Guide to Personal Finance — free book for physicians — moneymeetsmedicine.com/freebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
The biggest IPO in history couldn't get into the S&P 500 — and the rule that kept SpaceX out may have quietly saved you money.
Ready to play
Should I Invest in SpaceX? (Lessons from SpaceX IPO)
No transcript for this episode yet
Similar Episodes
No similar episodes found.